lymphedema treatment Market

The lymphedema treatment market is projected to reach US$ 11.58 billion by 2028 from US$ 8.15 billion in 2021; it is expected to grow at a CAGR of 5.1% from 2021 to 2028.

Market Overview

Lymphedema can arise due to harm or disturbance in lymphatic flow, as per the Cleveland Clinic report, which leads to swelling caused by lymph fluids pooling into soft tissues throughout the body. Although it can occur anywhere, the condition predominantly affects the arms and legs. Additionally, lymphedema can develop as a result of cancer treatments such as surgery and radiation, which is more commonly observed in oncology patients, as indicated in a report by the National Center for Biotechnology Information (NCBI). For instance, 1 out of 5 women who have survived breast cancer experience lymphedema. A report from the National Cancer Institute shows that 1 in 5 women who have survived breast cancer experience lymphedema, which is associated with radiation therapy to the chest wall, particularly in the treated breast. Patients with head and neck cancer are highly prone to lymphedema, with a prevalence rate as high as 75%, and significant risk factors being high-dose radiation and combined surgery. To reduce the risk of lymphedema, major players in the cancer treatment market are highly dedicated to developing innovative products and securing approvals for them, alongside the provision of highly effective and advanced cancer treatment options.

Market Dynamics  

The expanding lymphedema treatment market is due to the rising prevalence of secondary lymphedema and the growing availability of healthcare services and lymphedema management programs. Nevertheless, market growth is impeded by insufficient awareness. 

Market Segmentation

The global lymphedema treatment market is categorized into primary lymphedema and secondary lymphedema based on condition type, with the latter holding a greater market share in 2021. During the forecast period, the primary lymphedema segment is expected to have a higher compound annual growth rate (CAGR) in the lymphedema treatment market.  

The global lymphedema treatment market is divided into various treatment types, such as compression devices and bandaging, laser therapy, drug therapy, physiological procedures, debulking procedures, and others. The physiological procedures are further categorized as lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT), whereas debulking procedures are further categorized as surgical debulking, liposuction, and others. The compression devices and bandaging segment captured the largest market share in 2021, while the physiological procedure segment is predicted to have the highest compound annual growth rate (CAGR) during the forecast period. This is due to the effective treatment provided to lymphedema patients via LVA and VLNT, making them suitable treatment options for individuals with lymphedema.

The lymphedema treatment market is categorized based on end-users, such as hospitals, clinics, clinical research organizations (CROs), and others (ambulatory care centers and primary care centers). In 2021, the hospitals segment held the largest market share due to the launch of innovative products by leading players, which aimed to maximize resource utilization in hospitals. For instance, in September 2020, Paul Hartmann partnered with Apollo Hospitals Group in India and West China Hospitals to operate wound care clinics and ambulances, provide medical training, and offer products and services. This factor is expected to drive the growth of the lymphedema treatment market in the forecast period.

The report on the lymphedema treatment market was prepared by referring to various primary and secondary sources, including the National Center for Health Statistics, Indian Council of Medical Research, Centers for Disease Control and Prevention (CDC), the National Center for Biotechnology Information (NCBI), Industrial Biotechnology Leadership Forum, and World Health Organization (WHO).